Abbas F, El Kossi M, Jin JK, Sharma A, Halawa A. Recurrence of primary glomerulonephritis: Review of the current evidence. World J Transplant 2017; 7(6): 301-316 [PMID: 29312859 DOI: 10.5500/wjt.v7.i6.301]
Corresponding Author of This Article
Dr. Ahmed Halawa, Consultant Transplant Surgeon, DNB, FRCS (Ed), FRCS (Gen Surg), MD, MSc, Department of Transplantation Surgery, Sheffield Teaching Hospital, Herries Road, Sheffield S5 7AU, United Kingdom. ahmed.halawa@sth.nhs.uk
Research Domain of This Article
Transplantation
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. Dec 24, 2017; 7(6): 301-316 Published online Dec 24, 2017. doi: 10.5500/wjt.v7.i6.301
Recurrence of primary glomerulonephritis: Review of the current evidence
Fedaey Abbas, Mohsen El Kossi, Jon Kim Jin, Ajay Sharma, Ahmed Halawa
Fedaey Abbas, Department of Nephrology, Jaber El Ahmed Military Hospital, Safat 13005, Kuwait
Fedaey Abbas, Mohsen El Kossi, Jon Kim Jin, Ajay Sharma, Ahmed Halawa, Faculty of Health and Science, University of Liverpool, Institute of Learning and Teaching, School of Medicine, Liverpool L69 3GB, United Kingdom
Mohsen El Kossi, Doncaster Royal Infirmary, Doncaster DN2 5LT, United Kingdom
Jon Kim Jin, Nottingham Children Hospital, Nottingham NG7 2UH, United Kingdom
Ajay Sharma, Royal Liverpool University Hospitals, Liverpool L7 8XP, United Kingdom
Ahmed Halawa, Department of Transplantation Surgery, Sheffield Teaching Hospitals, Sheffield S5 7AU, United Kingdom
Author contributions: Abbas F designed the study, executed data collection, and writing the manuscript; El Kossi M, Jin JK and Sharma A reviewed and edited the manuscript; Halawa A contributed to conceptualization, designing of the study, supervising of the data collection and reviewing and editing of the manuscript.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Ahmed Halawa, Consultant Transplant Surgeon, DNB, FRCS (Ed), FRCS (Gen Surg), MD, MSc, Department of Transplantation Surgery, Sheffield Teaching Hospital, Herries Road, Sheffield S5 7AU, United Kingdom. ahmed.halawa@sth.nhs.uk
Telephone: +44-778-7542128 Fax: +44-114-2714604
Received: May 6, 2017 Peer-review started: May 10, 2017 First decision: July 20, 2017 Revised: November 8, 2017 Accepted: November 22, 2017 Article in press: November 22, 2017 Published online: December 24, 2017 Processing time: 229 Days and 14.2 Hours
Abstract
In view of the availability of new immunosuppression strategies, the recurrence of allograft glomerulonephritis (GN) are reported to be increasing with time post transplantation. Recent advances in understanding the pathogenesis of the GN recurrent disease provided a better chance to develop new strategies to deal with the GN recurrence. Recurrent GN diseases manifest with a variable course, stubborn behavior, and poor response to therapy. Some types of GN lead to rapid decline of kidney function resulting in a frustrating return to maintenance dialysis. This subgroup of aggressive diseases actually requires intensive efforts to ascertain their pathogenesis so that strategy could be implemented for better allograft survival. Epidemiology of native glomerulonephritis as the cause of end-stage renal failure and subsequent recurrence of individual glomerulonephritis after renal transplantation was evaluated using data from various registries, and pathogenesis of individual glomerulonephritis is discussed. The following review is aimed to define current protocols of the recurrent primary glomerulonephritis therapy.
Core tip: Renal transplantation is the best-known therapy for end stage renal disease, with the glomerulonephritis represents a major aetiology for its prevalence. Unfortunately, recurrence of the glomerulonephritis (GN) disease after renal transplantation represents a real devastating impact on allograft survival. A clear understanding of their pathogenesis, will help not only in ameliorating GN recurrence, but also improves allograft survival.
